Skip to main content
  • Contact Us
  • Vantage logo Sign Up
  • Subscriber Sign In
Evaluate Logo

navigation

  • COVID-19
    • COVID-19 Update
    • Evaluate Vantage COVID-19 Report
    • COVID-19 Stories from Evaluate Vantage
    • Evaluate’s Business Continuity Plan
  • What We Do
    • Commercial Intelligence
    • Products
      • Evaluate Pharma
      • Evaluate Omnium
      • Evaluate Epi
      • Japan Drug Forecasts
      • Europe Drug Forecasts
    • Evaluate Custom Solutions
    • Evaluate Vantage
      • News
      • Analysis
      • Policy & Pricing
      • Data Insights
      • Events
      • Medtech
      • Therapy Areas
      • Editorial Team
      • About Evaluate Vantage
    • Evaluate for Biotech
  • How We Can Help You
    • Pharma and Biotech
    • Medtech
    • Financial Services
    • Management Consultancies
    • Service Providers
    • Customer Testimonials
  • Thought Leadership
  • About Us
    • Press Releases
    • Media Coverage
    • Executive Team
    • Vision & History
    • Careers
      • Current Vacancies
  • Contact Us
  • Sign Up for Evaluate Vantage
  • Subscriber Sign In

 

Vantage logo

Vantage

  • Covid-19
    • Covid-19 Coverage
    • Evaluate Vantage COVID-19 Report
  • News
    • Snippets
    • Deals
    • Trial results
    • Patents and litigation
    • Corporate strategy
  • Analysis
    • Interviews
    • Spotlight
    • Vantage points
    • Vantage views
  • Data Insights
    • M&A
    • IPO
    • NME approvals
    • Quarterly shareprice performance
    • Venture financing
    • Vantage data points
    • Other data
  • Events
    • Company events
    • Conferences
    • Upcoming events
  • Medtech
  • Therapy Areas
  • About
    • Editorial team

Reata Pharmaceuticals

Thumbnail
January 21, 2021

Biopharma’s stock market winners and losers in 2020

Thumbnail
November 25, 2020

FDA sends Reata back to the drawing board

The need for another pivotal trial of omaveloxolone in Friedreich's ataxia looks increasingly likely.

Article image
Vantage logo
November 19, 2020

Some of biopharma’s biggest assets face a solo existence

A look at biotech’s most valued upartnered assets sees new entries from Allakos and some Covid-19 projects.

Article image
Vantage logo
October 05, 2020

Few clues to flotation fever in past performance

Investors are piling into biotech IPOs, but the track record of previous years' new issues shows how hard it is to pick winners.

Article image
Vantage logo
September 15, 2020

Marinus finds a path forward in rare epilepsies

Marinus celebrates pivotal trial success with ganaxolone, but a quick approval could depend on lenient regulators.

Article image
Vantage logo
March 24, 2020

Pivotal readouts threatened by Covid-19 represent a $20bn investment

Article image
Vantage logo
March 20, 2020

Clinical trial delays become reality as Covid-19 risk spreads

A Vantage analysis identifies 315 pivotal trials that, like Lexicon’s Scored and Soloist studies, risk never being completed.

Article image
Vantage logo
January 07, 2020

A handful of huge gains stand out among mid and small-cap biotechs

Drug makers from across the globe feature in 2019’s list of best performing small biotech stocks, from Galapagos to Daiichi Sankyo to Arrowhead.

Article image
Vantage logo
November 12, 2019

Reata’s worsened Cardinal results could still be good enough

The pivotal portion of bardoxolone’s Cardinal study can’t match earlier data, but is still sufficient for filing.

Vantage logo
November 04, 2019

Share price movers – October 2019

Article image
Vantage logo
October 15, 2019

Reata looks to outsmart Abbvie again

Fresh from buying omaveloxolone and bardoxolone rights back from Abbvie, Reata sees the first part of the puzzle fall into place.

  • Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device. Find out more.
Vantage logo
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up

Latest Reports

February 11, 2021

Evaluate Vantage Pharma, Biotech & Medtech 2020 in Review

December 10, 2020

Evaluate Vantage 2021 Preview

View more...

Editor's Picks

Vantage logo
February 10, 2021

2020 wins top of the froths for biotech stocks

Vantage logo
October 04, 2018

Biotech flotations remain in high demand

Vantage logo
February 04, 2021

Glaxo’s growth problem

Vantage logo
January 27, 2021

Go or no go? Oncology decisions ahead for the FDA

Vantage logo
February 05, 2021

Pfizer reveals its PD-1 secret

Open modal

Evaluate HQ
44-(0)20-7377-0800

Evaluate Americas
+1-617-573-9450

Evaluate APAC
+81-(0)80-1164-4754

Footer menu

  • Terms and Conditions
  • Privacy Policies
  • Cookie Policy

© Copyright 2021 Evaluate Ltd.